New Research Uncovers Biological Drivers of Heart Disease Risk

Researchers from the Brigham, the Broad Institute, and Stanford Medicine combined multiple sequencing and experimental techniques to map the relationship between known coronary artery disease (CAD) variants and the biological pathways they impact.

Read More...

Three Studies Find Statins Protect Against Cardiovascular Disease in High-Risk Groups

Brigham researchers are challenging the trend of deprescribing statins in people over 75 years of age. Ariela Orkaby, MD, MPH, led a trio of studies of statin use in older adults with chronic kidney disease, older adults with and without frailty, and adults with heart failure with preserved ejection fraction.

Read More...

New Method of Identifying Disease-associated Traits Could Lead to Better Targeted Therapeutics

Brigham researchers have developed a method for identifying hidden genetic contributors to disease by applying various stress tests to human blood cells. The evoked cellular response traits they observed pinpointed genes and pathways relevant to multiple cardiometabolic and inflammatory diseases.

Read More...

Combination of SGLT2i, GLP-1 RA, and Non-Steroidal MRA Proposed for Patients With Type 2 Diabetes and Albuminuria

After analyzing data from pivotal trials, researchers at Brigham and Women’s Hospital believe treatment with a combination SGLT2i, GLP-1 RA, and nonsteroidal MRA has the potential to improve survival in patients with type 2 diabetes and at least moderately increased albuminuria.

Read More...

Study Shows Semaglutide Reduces Cardiovascular Events in People With Overweight or Obesity but Not Diabetes

The Brigham was part of a trial that shows for the first time that the weight loss drug semaglutide lowers the incidence of death from cardiovascular causes in those with overweight or obesity but not diabetes. Jorge Plutzky, MD, discusses the findings and implications for clinical care.

Read More...

Inflammation At Least As Important As Cholesterol for Predicting CV Risk in Statin-intolerant Patients

Paul M. Ridker, MD, MPH, of the Center for Cardiovascular Disease Prevention at Brigham and Women’s Hospital, and colleagues found inflammation assessed by hsCRP predicted cardiovascular events and death at least as strongly as LDLC when comparing bempedoic acid with placebo in statin-intolerant patients.

Read More...

AI Model Detects Atrial Septal Defects From Electrocardiograms

Shinichi Goto, PhD, at Brigham and Women’s Hospital, and colleagues have developed a deep learning–based model that detects subtle changes in standard 12-lead electrocardiography data to flag patients who should undergo echocardiography to evaluate possible atrial septal defect.

Read More...

The Brigham Keeps Women’s Cardiovascular Health in the Spotlight

The fact that cardiovascular disease is the leading cause of death in women is wildly underappreciated, says the Brigham’s JoAnn E. Manson, MD, MPH, DrPH. Dr. Manson has led many seminal research projects focused on women’s health and set the foundation for related advances at the Brigham today.

Read More...

Initial Decline in eGFR With Dapagliflozin Not Concerning in Patients With Heart Failure and LVEF >40%

Brigham and Women’s Hospital researchers report an initial decline in estimated glomerular filtration rate (eGFR) on initiation of dapagliflozin was not associated with adverse cardiovascular or kidney outcomes and did not appear to alter the long-term trajectory of eGFR decline.

Read More...